Clinical Trial Update: Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SBRT with Becotatug Vedotin (MRG003) in EGFR-positive oligometastatic cancer patients is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oligometastatic Cancer

Drugs mentioned

• Becotatug Vedotin (MRG003) (becotatug vedotin)

Snippet

Sponsor: Ming-Yuan Chen | Conditions: Oligo-metastatic Cancer | Phase 3 | Status: RECRUITING